Business Wire

Ecron Acunova to offer end-to-end capabilities as ‘Navitas Life Sciences’

Jaa

Ecron Acunova (EA), a fully owned subsidiary of TAKE Solutions and a globally recognized full service CRO with Clinical and BA/BE expertise, announced that it would be consolidating its capabilities with TAKE’s niche Life Sciences brand Navitas and Intelent to form a unified go-to-market entity – Navitas Life Sciences.

EA’s significant Clinical capabilities, having conducted over 1300 studies including BA/BE, NIS, and phase II – IV in its state-of-the-art and audited facilities, will be augmented by legacy brands Navitas’s technology led solutions across Clinical, Regulatory and Safety, and Intelent’s big data and analytics expertise to form the 360 degree service provider Navitas Life Sciences. The unified Navitas Life Sciences will serve as an end-to-end strategic partner for Life Sciences companies to help them address their critical challenges and achieve their desired outcomes.

Marty Boom, Managing Director, Ecron Acunova, said, “Capitalizing on the phenomenal growth opportunities in the Life Sciences industry calls for diverse capabilities. The unification of Ecron Acunova, Navitas and Intelent will enable a seamless consolidation of capabilities in the form of Navitas Life Sciences, which will enable us to offer clients a full-service coverage of the Pharma and Biotech R&D market.”

Ram Yeleswarapu, President & CEO, TAKE Solutions, said,We are proud to bring together our substantial and niche capabilities under the unified ambit of Navitas Life Sciences to present our client with truly transformational, flexible and adaptable end-to-end offerings. In addition to our technology driven offerings and insights derived from our world-class proprietary industry networks, our clients now also be able to benefit from the consolidated brand’s proven clinical capabilities and trial experiences.”

About Navitas Life Sciences

Navitas Life Sciences, a wholly owned subsidiary of TAKE Solutions, works as a strategic partner for large and mid-sized Life Sciences organizations to address critical challenges and achieve desired outcomes in Clinical, Regulatory and Safety. Navitas’ technology-led Life Sciences services are augmented with the full-service CRO with Clinical & BA/BE capabilities, and Life Sciences data analytics expertise of legacy brands Ecron Acunova and Intelent to deliver flexible, scalable and innovative solutions for its global clients.

Navitas Life Sciences’ expertise spans more than 1300 studies including BA/BE, NIS, and phase II – IV, and 70,000 regulatory submissions. The company’s unique proprietary network forums that include 300+ professionals from 100+ life sciences companies generate insights that help members prepare for the future of the industry. Navitas Life Sciences seamlessly combining best-in-class processes, meaningful and unique industry insight, innovative technology, exacting analytics and a customer-centric culture. For more information, visit www.navitaslifesciences.com

About TAKE Solutions

TAKE Solutions is a globally recognized knowledge intensive player, delivering comprehensive and niche solutions in Life Sciences (LS). TAKE offers IP-based software and extensive knowledge-based solutions to enable efficient Clinical, Regulatory, Safety outcomes for global clients. TAKE encompasses specialized capabilities under its Life Sciences business Navitas, whose technology-led Life Sciences services across Clinical, Regulatory and Safety are augmented by full-service CRO with Clinical & BA/BE capabilities and Big Data analytics expertise of its legacy brands Ecron Acunova and Intelent. Navitas Life Sciences delivers flexible and scalable solutions by seamlessly combining best-in-class processes, meaningful and unique industry insight, innovative technology, exacting analytics and a customer-centric culture.

TAKE’s significant recognitions include a patent win from the United States Patent and Trademark Office (USPTO) for its ‘Method for Optimizing Clinical Data Standardization’, a ‘Leader’ certification in Drug Safety Services & Life Sciences R&D IT Outsourcing from IDC, recognition as the ‘Dream Employer of the Year’ at the World HRD Congress, the title of ‘Most Admired Brand –IT’ from the Asian Customer Engagement Forum and a Special Commendation for excellence in Corporate Governance from the Golden Peacock Awards. With its global headquarters in Chennai, India, TAKE has a proven track record of delivering world-class solutions to more than 400 customers worldwide, including 9 of the top 10 global Pharma companies. For more information, please visit www.takesolutions.com.

Contact information

Navitas Life Sciences
Birgit Mund
+49 69 6680 300
birgit.mund@navitaslifesciences.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Rimini Street Expands Investment and Operations in Europe19.10.2017 01:00Tiedote

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the appointment of industry leader Marc Chesover as general manager of Europe, the Middle East and Africa (EMEA). The Company also announced the launch of its French subsidiary, hiring of new staff and opening of its new office in Paris, France. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006654/en/ Rimini Street Expands Investment and Operations in Europe (Photo: Business Wire) Enterprise Software Veteran Leads EMEA Operations Rimini Street’s new general manager, Marc Chesover, will lead the Company’s sales and service delivery operations across EMEA, and the next p

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy19.10.2017 00:43Tiedote

Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006639/en/ CAR T therapy is a breakthrough in hematologic cancer treatment in which

IFF Launches Re-Imagine…™ Programs to Tap Unmet Consumer Opportunities, Speed Innovation18.10.2017 23:15Tiedote

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, launched their Re-Imagine programs to accelerate innovation and increase agility to capture unmet opportunities in the changing food and beverage market. Based on a combination of future trends analysis, consumer insights, and a modernized cross-category development process, the programs guide the Company’s research and development efforts to ensure an innovation pipeline that addresses evolving consumer needs and desires. “The Re-Imagine programs area tangible expression of our commitment to advance taste for our customers – and consumers,” said IFF Chairman and CEO Andreas Fibig. “It is another way in which we show how we are dedicated to being our customers’ partner of choice as we progress on our business strategy, imbu

Sparkol Launches VideoScribe 318.10.2017 16:24Tiedote

Introducing VideoScribe Version 3 by Sparkol. Already used by over two million people across the world to create engaging explainer videos, Version 3 of the highly intuitive software comes packed full of new features, including: An improved user experience and slick UI - animate easier than ever before Enhanced search - find exactly the image you need in record time Intelligent image recommendations - focus your creativity on your video instead Smoother performance - maximum productivity when using the software VideoScribe customers include the world’s largest brands (HP, BBC, Sky and the University of British Columbia), businesses across every sector, leading education providers, award-winning teachers, charities, campaigners, and coun

Piraeus Bank: Agreement for the Sale of Serbian Operations18.10.2017 16:06Tiedote

Piraeus Bank announces that it has entered into an agreement to sell its Serbian banking and leasing operations to Direktna Banka A.D., a local Serbian banking group that has been strongly growing its presence in the market, for a total cash consideration between €58mn up to €61mn, depending on the financial performance of the divested assets until completion of the transaction, through a combination of direct sale price and simultaneous reduction of capital in Piraeus Bank Beograd AD. The transaction is conditional upon the usual corporate and regulatory approvals, including those of the National Bank of Serbia and the Hellenic Financial Stability Fund. The transaction represents another step towards the implementation of Piraeus Bank’s Restructuring Plan commitments, as those were agreed with the Directorate General of Competition of the European Commission. The transactio

Introducing InVision Studio, The World’s Most Powerful Screen Design Tool18.10.2017 16:01Tiedote

InVision, the product design platform powering the world’s best digital experiences, today introduced Studio, a powerful new tool that will change the way screen design is done. InVision Studio was created by working closely with the world’s best design teams and finding inspiration in how they create beloved digital products. The launch of Studio comes at a time when modern organizations are shaping and redefining entire markets through their focus on digital customer experience. InVision already powers the product design process of more than 3 million people at tens of thousands of companies, including eighty percent of the Fortune 100 and brands like Airbnb, Uber, HBO, Amazon, IBM, Nike, and Slack. This new product reflects a major evolution of the digital product design workflow. With Studio, InVision has developed an end-to-end platform for designing digit

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme